Clinic Trial for QLS-111 a Success

We’re happy to announce recent successes in phase II clinical trials for a drug that was developed, in part, here in our department. The results of a recent Phase 2 clinical trial for the glaucoma drug QLS-111 met the primary endpoints for the treatment of open angle glaucoma (POAG) and ocular hypertension (OHT).

QLS-111 is based on work carried out by Dr. Peter I. Dosa and collaborators at the Mayo Clinic. Dr. Dosa is a Research Associate Professor in the Department of Medicinal Chemistry and in the ITDD. He is also the Associate Program Director of Medicinal Chemistry within the ITDD.

You can read the original news release by Qlaris Bio here. Qlaris Bio licensed the patents covering the technology in 2019 from the University of Minnesota. The drug demonstrated a favorable safety and tolerability profile, and these promising clinical trial findings continue to offer hope for those diagnosed with glaucoma.

"I'm very excited that Qlaris thinks the clinical trial results are promising”, said Dosa of the news.

In February, Qlaris Bio will give an update at the Glaucoma 360 New Horizons Forum 2025 in San Francisco, CA.

We’re proud of our department’s involvement in the development of this potentially life-changing therapeutic and we’re excited to see what the future holds for QLS-111. 

Congratulations to Dr. Dosa and all his collaborators!